230 related articles for article (PubMed ID: 32954617)
1. Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
Li C; Zhou Z; Neuen BL; Yu J; Huang Y; Young T; Li J; Li L; Perkovic V; Jardine MJ; Keay L; Markoulli M; Rosenthal N; Capuano G; Yavin Y; Neal B; Arnott C
Diabetes Obes Metab; 2021 Jan; 23(1):252-257. PubMed ID: 32954617
[TBL] [Abstract][Full Text] [Related]
2. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
4. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
Forbes AK; Suckling RJ; Hinton W; Feher MD; Banerjee D; Cole NI; de Lusignan S; Swift PA
Diabetes Obes Metab; 2023 Aug; 25(8):2310-2330. PubMed ID: 37202870
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
11. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
13. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials.
Gohari S; Ismail-Beigi F; Mahjani M; Ghobadi S; Jafari A; Ahangar H; Gohari S
BMC Endocr Disord; 2023 Nov; 23(1):257. PubMed ID: 37996879
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
Liu Y; An C; Liu P; Yang F; Zhao Q
Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
[TBL] [Abstract][Full Text] [Related]
16. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
[TBL] [Abstract][Full Text] [Related]
17. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
[TBL] [Abstract][Full Text] [Related]
18. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
